2025-03-27T10:22:40-05:00 2024-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2024-01-01 812076517 INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN INST 3016057571 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 ELIZABETH GAROFALO BOARD CHAIR 3016057571 2025-03-27 1 0 ELIZABETH W HELLER P00397829 3019519090 2024 2025-03-06 01:10:19Z X ELIZABETH GAROFALO 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 648518 0 X WWW.IACTC.ORG X 2016 DE SEE PART III, LINE 1. 10 10 12 10 0 0 1126270 500972 258947 96555 78674 45177 0 5814 1463891 648518 134894 528 0 0 2084411 1820705 13329 7736 504037 1064161 882097 3296795 2711066 -1832904 -2062548 3501048 1381300 135918 78718 3365130 1302582 X TO FUNCTION AS A NONPROFIT EDUCATIONAL, SCIENTIFIC AND RESEARCH ORGANIZATION TO ENABLE AND ADVANCE PEDIATRIC CLINICAL RESEARCH PRESCRIBED BY REGULATION THROUGH: (CONTINUED ON SCHED.O) 0 0 1144855 528 96555 DURING THIS TIME PERIOD, THE ORGANIZATION MADE APPLICATIONS FOR CONTRIBUTIONS AND MEMBERSHIP FEES. FOUR MEMBERSHIP FEES WERE RECEIVED AND PLEDGED IN 2024. THROUGHOUT 2024, CLINICAL PROGRAM GUIDANCE SERVICES WERE PERFORMED FOR MEMBERS AND NON-MEMBERS. THERE WERE ADDITIONAL FINANCIAL CONTRIBUTIONS MADE IN 2024 FROM EDUCATIONAL GRANTS.THE ORGANIZATION PROVIDES EXPERT GUIDANCE AND INPUT ON PEDIATRIC CLINICAL DEVELOPMENT PLANS AND PEDIATRIC CLINICAL TRIALS WITH THE GOAL OF IMPROVING THE PROCESSES AND ACCELERATING THE DEVELOPMENT OF INNOVATIVE PRODUCTS FOR USE IN CHILDREN. ADDITIONALLY, THE ORGANIZATION ALSO CONNECTS QUALIFIED CLINICAL TRIAL SITES IN OUR PEDIATRIC CLINICAL TRIAL SITE NETWORK WITH CLINICAL TRIALS FOR A VARIETY OF BIOPHARMACEUTICAL COMPANIES.THE ORGANIZATION UTILIZES ITS NETWORK OF EXPERTS TO CONVENE WORKING GROUPS TO TACKLE PROBLEMS IN PEDIATRIC CLINICAL DEVELOPMENT COMMON ACROSS A VARIETY OF STAKEHOLDERS, THAT OTHERWISE WOULD NOT BE ADDRESSED IN A PRECOMPETITIVE MANNER. 1144855 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 17 0 1 12 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X LAURA LOPEZ 3016057571 11810 GRAND PARK AVENUE 500 NORTH BETHESDA MD 20852 ELIZABETH GAROFALO CHAIRWOMAN 3.00 X X 0 0 0 MARTHA BRUMFIELD SECRETARY/TREASURER 3.00 X X 0 0 0 BARRY BROOKS DIRECTOR 3.00 X 0 0 0 JAMES POMFRET DIRECTOR 3.00 X 0 0 0 MAX COPPES DIRECTOR 3.00 X 0 0 0 JEFF BARRETT DIRECTOR 3.00 X 0 0 0 DANIEL JORGENSEN DIRECTOR 3.00 X 0 0 0 TAMAROH LEWIS DIRECTOR 3.00 X 0 0 0 STEPHANIE DAVIS DIRECTOR 3.00 X 0 0 0 KRISTEN SWINGLE DIRECTOR 3.00 X 0 0 0 VIVIANNA GUZMAN EXECUTIVE DIRECTOR 40.00 X 308132 0 13328 ALBERT JOHN ALLEN CMO 20.00 X 130020 0 4334 LAURA LOPEZ CFAO 40.00 X 198535 0 27182 CALLIE HEATON DIR. CLINICAL PROJECT MGMT UNTIL 11/24 40.00 X 162600 0 7841 ANGELA PRICE DIR. CLINICAL SITE NETWORK 40.00 X 149721 0 18779 GABRIELA TULLOCH SR. MGR. CLINICAL SITE NET 40.00 X 138150 0 22164 1087158 0 93628 6 0 1 0 FLEX PROFESSIONALS 10300 EASTON PLACE SUITE 440 FAIRFAX VA 22030 TEMPORARY STAFFING AGENCY 104726 1 350000 150972 500972 CLINICAL PROGRAM GUIDA 900099 96555 96555 96555 45177 45177 OTHER REVENUE 900099 5814 5814 5814 648518 96555 0 50991 X 528 528 681531 479709 136087 65735 926336 200016 510819 215501 29249 8939 13911 6399 72874 20204 35107 17563 110715 45959 44884 19872 13346 7761 3375 2210 82661 48020 20948 13693 36000 18528 8804 8668 7736 7736 473705 243801 115846 114058 17027 6773 7374 2880 161369 35715 110293 15361 29631 13643 10017 5971 40023 3283 33362 3378 1223 490 733 467 467 24311 11486 7813 5012 MISCELLANEOUS 2334 2334 2711066 1144855 1062174 504037 567036 536010 2223516 508820 558560 35368 250000 82969 83485 5045 5045 2801 0 30798 2985 3501048 1381300 107685 75391 28233 3327 135918 78718 X 2815130 752582 550000 550000 3365130 1302582 3501048 1381300 -2062548 0 X 0 0 0 X 5953742 4045844 2354048 1126270 500972 13980876 5953742 4045844 2354048 1126270 500972 13980876 7046858 6934018 49330 13051 19941 78674 45177 206173 5814 5814 14192863 3638749 0.48860 0.51300 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 37484 37484 2665846 2703330 285167 71292 0 0 314173 285167 599340 899010 36329 37484 73813 78543 71292 149835 224753 5045 5045 0 0 LEASE LIABILITY 3327 3327 648518 0 648518 0 648518 2711066 0 2711066 0 2711066 X X X 0 0 0 0 0 0 0 1 0 VIVIANNA GUZMAN EXECUTIVE DIRECTOR 301882 0 6250 0 0 0 0 0 13328 0 321460 0 0 0 LAURA LOPEZ CFAO 194368 0 4167 0 0 0 8360 0 18822 0 225717 0 0 0 CALLIE HEATON DIR. CLINICAL PROJECT MGMT UNTIL 11/ 162600 0 0 0 0 0 6365 0 1476 0 170441 0 0 0 ANGELA PRICE DIR. CLINICAL SITE NETWORK 149721 0 0 0 0 0 5046 0 13733 0 168500 0 0 0 GABRIELA TULLOCH SR. MGR. CLINICAL SITE NET 138150 0 0 0 0 0 4910 0 17254 0 160314 0 0 0 PART I, LINE 7 VIVIANNA GUZMAN AND LAURA LOPEZ BOTH RECEIVED A ONE-TIME APPRECIATION BONUS IN AUGUST 2024 (DISCRETIONARY BONUS) FOR $6,250 AND $4,167 RESPECTIVELY. FORM 990, PART III, LINE 1 CONTINUATION: (1) DEVELOPING, ADVANCING, ACCUMULATING AND MAINTAINING SCIENTIFIC DESCRIPTION OF ORGANIZATION MISSION: TO ESTABLISH AND DRIVE INNOVATION TO IMPROVE AND EXPEDITE PEDIATRIC DRUG DEVELOPMENT. OUR WORK IS NOT JUST ABOUT ADVANCING THE DEVELOPMENT OF NEW THERAPIES; IT'S ABOUT GIVING CHILDREN WITH MEDICAL CONDITIONS A BETTER CHANGE AT A HIGH QUALITY OF LIFE, ALLOWING THEM TO FLOURISH DESPITE THEIR CONDITION, WHICH FOR SOME, CAN BE A MATTER OF LIFE OF DEATH. ENGAGING SUBJECT MATTER EXPERTS, ACADEMICS, REGULATORY AGENCIES, DRUG DEVELOPERS AND PATIENT ADVOCATES IN OUR MISSION. TOGETHER, FOSTERING AN ENVIRONMENT THAT FINDS SOLUTIONS TO THE MANY CHALLENGES FOR SAFE AND EFFECTIVE PEDIATRIC DRUG DEVELOPMENT, AND (2) ENGAGING IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH CORPORATIONS MAY BE ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW. AS AMENDED FROM TIME TO TIME. ALSO, TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY PERMITTED FOR ORGANIZATIONS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS THREE CLASSES OF MEMBERS (1) FOUNDING MEMBERS, CONSISTING OF CRITICAL PATH INSTITUTE, ELIZABETH GAROFALO, M.D., AND MARTHA BRUMFIELD, PH.D.; (2) SUSTAINING MEMBERS, CONSISTING OF ORGANIZATIONS THAT PROVIDE SUBSTANTIAL UNRESTRICTED FUNDS AS DUES TO THE CORPORATION OVER AN INITIAL MEMBERSHIP TERM OF FIVE YEARS, WITH ANNUAL CONTINUATION OPTION; AND (3) GENERAL MEMBERS, CONSISTING OF THOSE SUPPORTING THE PURPOSE AND ACTIVITIES OF THE CORPORATION OVER A ONE-YEAR TERM OF MEMBERSHIP. FORM 990, PART VI, SECTION A, LINE 7A FOUNDING AND SUSTAINING MEMBERS HAVE THE RIGHT TO VOTE ON THE BOARD OF DIRECTOR NOMINEES. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE AUDIT AND COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C TO ENSURE THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH CHARITABLE PURPOSES AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE TAX-EXEMPT STATUS, PERIODIC REVIEWS SHALL BE CONDUCTED. THE PERIODIC REVIEWS SHALL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS: (1) WHETHER COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND THE RESULT OF ARM'S LENGTH BARGAINING, AND (2) WHETHER PARTNERSHIPS, JOINT VENTURES AND ARRANGEMENTS WITH MANAGEMENT ORGANIZATIONS CONFIRM TO THE CORPORATION'S WRITTEN POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE INVESTMENT OR PAYMENTS FOR GOODS AND SERVICES, FURTHER CHARITABLE PURPOSE AND DO NOT RESULT IN INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR IN AN EXCESS BENEFIT TRANSACTION. WHEN CONDUCTING THE PERIODIC REVIEWS, THE ORGANIZATION MAY, BUT NEED NOT, USE OUTSIDE ADVISORS. IF OUTSIDE ADVISORS ARE USED, THEIR USE SHALL NOT RELIEVE THE GOVERNING BOARD OF ITS RESPONSIBILITY FOR ENSURING PERIODIC REVIEWS ARE CONDUCTED. FORM 990, PART VI, SECTION B, LINE 15 THE TOP MANAGEMENT OFFICIAL, EXECUTIVE DIRECTOR, HAS COMPENSATION REVIEWED BY AN INDEPENDENT PERSON (HR CONSULTANT AND AUDIT AND COMPENSATION COMMITTEE CHAIR, OR BOARD OF DIRECTORS APPOINTEE), COMPARABILITY DATA FROM BENCHMARKING AND DELIBERATION AND DECISION IS REFLECTED IN THE BOARD MEETING MINUTES. THE APPROVED PAY RATE UPON HIRE IS VALIDATED BY A SIGNED OFFER LETTER BY THE BOARD CHAIRPERSON FOR THE EXECUTIVE DIRECTOR. FOR THE CMO AND CFO POSITIONS, THE EXECUTIVE DIRECTOR, OR THE BOARD OF DIRECTORS CHAIRPERSON, WILL EVALUATE THE BENCHMARKING AND SIGN THE OFFER LETTER FOR THE APPROVED PAY RATE. FORM 990, PART VI, SECTION C, LINE 19 THE ARTICLES OF INCORPORATION, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G COMMUNICATION & PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 7,220. MANAGEMENT AND GENERAL EXPENSES 3,094. FUNDRAISING EXPENSES 2,061. TOTAL EXPENSES 12,375. PAYROLL & BENEFIT SERVICES: PROGRAM SERVICE EXPENSES 3,272. MANAGEMENT AND GENERAL EXPENSES 1,742. FUNDRAISING EXPENSES 1,411. TOTAL EXPENSES 6,425. RECRUITMENT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 36. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 36. CONTRACTOR - PHYSICIAN: PROGRAM SERVICE EXPENSES 28,625. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 28,625. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 204,684. MANAGEMENT AND GENERAL EXPENSES 110,974. FUNDRAISING EXPENSES 110,586. TOTAL EXPENSES 426,244.